Evidence-based pharmacotherapy of treatment-resistant unipolar depression

References

• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. 2005. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 255:387–400.
   PubMed Web of Science ®Google Scholar
• Adli M, Pilhatsch M, Bauer M, Koberle U, Ricken R, Janssen G, Ulrich S, Bschor T. 2008. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry. 41:252–257.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Berwish NJ. 1989. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry. 22:21–25.
   PubMed Web of Science ®Google Scholar
• APA. 2010. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Arlington (VA): American Psychiatric Association (APA).
   Google Scholar
• Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. 2001. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 62:448–452.
   PubMed Web of Science ®Google Scholar
• Aronson R, Offman HJ, Joffe RT, Naylor CD. 1996. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 53:842–848.
   PubMed Web of Science ®Google Scholar
• Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, Zohar J, Mendlewicz J, Serretti A. 2016. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 189:224–232.
   PubMed Web of Science ®Google Scholar
• Ballesteros J, Callado LF. 2004. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord. 79:137–147.
   PubMed Web of Science ®Google Scholar
• Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC. 2011. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry. 72:1405–1412.
   PubMed Web of Science ®Google Scholar
• Barbosa L, Berk M, Vorster M. 2003. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 64:403–407.
   PubMed Web of Science ®Google Scholar
• Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. 2014. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 28:331–342.
   PubMed Web of Science ®Google Scholar
• Bauer M, Dell'Osso L, Kasper S, Pitchot W, Dencker Vansvik E, Köhler J, Jørgensen L, Montgomery SA. 2013a. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord. 151:209–219.
   PubMed Web of Science ®Google Scholar
• Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. 2010. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 127:19–30.
   PubMed Web of Science ®Google Scholar
• Bauer M, Goetz T, Glenn T, Whybrow PC. 2008. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol. 20:1101–1114.
   PubMed Web of Science ®Google Scholar
• Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, et al. 2013b. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 14:334–385.
   PubMed Web of Science ®Google Scholar
• Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ, et al. 2015. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 16:76–95.
   PubMed Web of Science ®Google Scholar
• Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. 1997. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand. 95:288–296.
   PubMed Web of Science ®Google Scholar
• Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P, Nieto I, Bellivier F, Bubrovsky M, Vaiva G, et al. 2015. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 171:137–141.
   PubMed Web of Science ®Google Scholar
• Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. 2010. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 167:281–288.
   PubMed Web of Science ®Google Scholar
• Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD. 2011. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry. 72:1086–1094.
   PubMed Web of Science ®Google Scholar
• Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. 2011. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 9:90
   PubMed Web of Science ®Google Scholar
• Bschor T, Baethge C. 2010. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand. 121:174–179.
   PubMed Web of Science ®Google Scholar
• Bschor T, Bauer M, Adli M. 2014. Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int. 111:766–775.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, et al. 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 373:746–758.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Hawton K, Stockton S, Geddes JR. 2013. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 346:f3646.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. 2011. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 71:43–64.
   PubMed Web of Science ®Google Scholar
• Crossley NA, Bauer M. 2007. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 68:935–940.
   PubMed Web of Science ®Google Scholar
• Dold M, Kautzky A, Bartova L, Souery D, Mendlewicz J, Serretti A, et al. 2015. Psychopharmakologische Behandlungsstrategien bei unipolarer Depression an europäischen Universitätskliniken – eine pharmakoepidemiologische multizentrische Querschnittsstudie [in German]. Poster presented at the DGPPN congress, Berlin, Germany, 25–28.11.2015.
   Google Scholar
• Dold M, Leucht S. 2014. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 17:33–37.
   PubMedGoogle Scholar
• Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. 1989. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 25:71–79.
   PubMedGoogle Scholar
• Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. 2015. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 84:72–81.
   PubMed Web of Science ®Google Scholar
• Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM. 2009. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol. 29:362–367.
   PubMed Web of Science ®Google Scholar
• Galling B, Calsina Ferrer A, Abi Zeid Daou M, Sangroula D, Hagi K, Correll CU. 2015. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 14:1587–1608.
   PubMed Web of Science ®Google Scholar
• Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. 2010. International consensus study of antipsychotic dosing. Am J Psychiatry. 167:686–693.
   PubMed Web of Science ®Google Scholar
• Gerhard T, Akincigil A, Correll CU, Foglio NJ, Crystal S, Olfson M. 2014. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry. 75:490–497.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:56–62.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, et al. 2011. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 44:195–235.
   Web of Science ®Google Scholar
• Hieronymus F, Nilsson S, Eriksson H. 2015. A mega-analysis of fixed-dose trials reveals dose-dependency, a rapid onset of action and a respectable effect size for the symptom-reducing effect of SSRIs in adult major depression. Poster presented at the IFMAD, Prague, Czech Republic, 02–04.12.2015.
   Google Scholar
• Holma KM, Haukka J, Suominen K, Valtonen HM, Mantere O, Melartin TK, Sokero TP, Oquendo MA, Isometsä ET. 2014. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder. Bipolar Disord. 16:652–661.
   PubMed Web of Science ®Google Scholar
• Kasper S, Akimova E. 2013. The role of atypical antipsychotics in inadequate-response and treatment-resistant depression. In: Kasper S, Montgomery S, editors. Treatment-resistant depression. Chichester: Wiley-Blackwell; p. 107–128.
   Google Scholar
• Kasper S, Montgomery S. 2013. Treatment-resistant depression. Chichester: Wiley-Blackwell.
   Google Scholar
• Kato M, Chang CM. 2013. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs. 27:S11–S19.
   PubMed Web of Science ®Google Scholar
• Kessing LV, Sondergard L, Kvist K, Andersen PK. 2005. Suicide risk in patients treated with lithium. Arch Gen Psychiatry. 62:860–866.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S. 2012. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP international pharmacovigilance program. Int J Neuropsychopharmacol. 15:449–457.
   PubMed Web of Science ®Google Scholar
• Kovess-Masfety V, Alonso J, Angermeyer M, Bromet E, de Girolamo G, de Jonge P, Demyttenaere K, Florescu SE, Gruber MJ, Gureje O, et al. 2013. Irritable mood in adult major depressive disorder: results from the world mental health surveys. Depress Anxiety. 30:395–406.
   PubMed Web of Science ®Google Scholar
• Landen M, Bjorling G, Agren H, Fahlen T. 1998. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 59:664–668.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. 2015. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 386:2404–2412.
   PubMed Web of Science ®Google Scholar
• Licht RW, Qvitzau S. 2002. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl). 161:143–151.
   PubMed Web of Science ®Google Scholar
• Lopes Rocha F, Fuzikawa C, Riera R, Ramos MG, Hara C. 2013. Antidepressant combination for major depression in incomplete responders – a systematic review. J Affect Disord. 144:1–6.
   PubMed Web of Science ®Google Scholar
• McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. 2012. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 379:721–728.
   PubMed Web of Science ®Google Scholar
• Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S. 2004. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 161:826–835.
   PubMed Web of Science ®Google Scholar
• Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M. 2012. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 73:353–357.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Leslie DL, Rosenheck RA. 2009. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. J Clin Psychiatry. 70:906–912.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:382–389.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, et al. 2007. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 22:323–329.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. 2014. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 29:470–482.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. 2014. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 168:269–275.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. 2009. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 166:980–991.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA. 2012. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 27:125–133.
   PubMed Web of Science ®Google Scholar
• NICE. 2009. Depression in adults: the treatment and management of depression in adults. National Collaborating Centre for Mental Health.
   Google Scholar
• Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, et al. 2006. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 163:1519–1530.
   PubMed Web of Science ®Google Scholar
• Otuyelu E, Foldvari A, Szabo E, Sipos V, Edafiogho P, Szucs M, Dome P, Rihmer Z, Sandor J. 2015. Antidepressant drugs and teenage suicide in Hungary: time trend and seasonality analysis. Int J Psychiatry Clin Pract. 19:221–225.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC. 2015. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 172:1251–1258.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M, Thase ME. 2008. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry. 63:699–704.
   PubMed Web of Science ®Google Scholar
• Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M. 2005. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 25:336–341.
   PubMed Web of Science ®Google Scholar
• Rocha FL, Fuzikawa C, Riera R, Hara C. 2012. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 32:278–281.
   PubMed Web of Science ®Google Scholar
• Rombold F, Lauterbach E, Felber W, Mueller-Oerlinghausen B, Ahrens B, Bronisch T, Kilb B, Lewitzka U, Richter K, Broocks A, et al. 2014. Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders. Int J Psychiatry Clin Pract. 18:300–303.
   PubMed Web of Science ®Google Scholar
• Romera I, Perez V, Menchon JM, Schacht A, Papen R, Neuhauser D, Abbar M, Svanborg P, Gilaberte I. 2012. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol. 32:479–486.
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Booij J, v Weert HC, Reitsma JB, Franssen EJ, Michel MC, Schene AH. 2009. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology. 34:999–1010.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, et al. 2011. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 168:689–701.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, et al. 2006. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 354:1231–1242.
   PubMed Web of Science ®Google Scholar
• Santos MA, Rocha FL, Hara C. 2008. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 10:187–190.
   PubMedGoogle Scholar
• Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickels K. 2001. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol. 16:137–143.
   PubMed Web of Science ®Google Scholar
• Shine B, McKnight RF, Leaver L, Geddes JR. 2015. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 386:461–468.
   PubMed Web of Science ®Google Scholar
• Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. 1999. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 9:83–91.
   PubMed Web of Science ®Google Scholar
• Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, et al. 2007. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 68:1062–1070.
   PubMed Web of Science ®Google Scholar
• Souery D, Papakostas GI, Trivedi MH. 2006. Treatment-resistant depression. J Clin Psychiatry. 67:16–22.
   PubMed Web of Science ®Google Scholar
• Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, et al. 2011a. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 31:512–516.
   PubMed Web of Science ®Google Scholar
• Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Kasper S, Montgomery S, Zohar J, Mendlewicz J. 2011b. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry. 12:364–375.
   PubMed Web of Science ®Google Scholar
• Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. 2013. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 10:e1001403.
   PubMed Web of Science ®Google Scholar
• Sugawara H, Sakamoto K, Harada T, Ishigooka J. 2010. Predictors of efficacy in lithium augmentation for treatment-resistant depression. J Affect Disord. 125:165–168.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. 1997. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 58:23–29.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H. 2015. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 76:1224–1231.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, et al. 2006a. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 354:1243–1252.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. 2006b. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 163:28–40.
   PubMed Web of Science ®Google Scholar
• Turner P, Kantaria R, Young AH. 2014. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol. 28:85–98.
   PubMed Web of Science ®Google Scholar
• Wang HR, Woo YS, Ahn HS, Ahn IM, Kim HJ, Bahk WM. 2015. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 18:pyv023.
   Web of Science ®Google Scholar
• WHO. 2001. World Health Report 2001. Mental health – new understanding, new hope. Genf: World Health Organisation.
   Google Scholar
• Wiethoff K, Bauer M, Baghai TC, Moller HJ, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, et al. 2010. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J Clin Psychiatry. 71:1047–1054.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, et al. 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 21:655–679.
   PubMed Web of Science ®Google Scholar
• Zhou XP, Keitner GIP, Qin BM, Ravindran AVP, Bauer MP, Del Giovane CP, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P. 2015. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 18:pyv060.
   PubMed Web of Science ®Google Scholar